State-licensed medical marijuana reclassified by the Trump administration as a less dangerous drug

"The move removes these products from the Schedule I category, which includes what the government considers to be high-risk and dangerous drugs such as heroin, LSD and ecstasy, to the lower-risk category of Schedule III."

"Under the CSA, the Schedule I classification includes drugs with no currently accepted medical use and a high potential for abuse."

"Schedule III, meanwhile, applies to drugs, such as ketamine and anabolic steroids, that the government deems to have a moderate to low potential for physical and psychological dependence."

"This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with more medical treatment options."

The Trump administration officially reclassified state-licensed medical marijuana products under the Controlled Substances Act, moving them from Schedule I to Schedule III. This change does not legalize medical or recreational cannabis federally but reduces barriers for research. Schedule I drugs are considered high-risk with no accepted medical use, while Schedule III drugs have a moderate to low potential for abuse. The reclassification aims to facilitate research on marijuana's safety and efficacy, expanding access to medical treatment options.

Read at www.scientificamerican.com